FYLM treatment delays the resistance of EGFR-mutant cell lines and EGFR-mutant tumor-bearing mice to osimertinib by inhibiting the Wnt/EGFR pathway (Shi et al., 2023). This evidence concerns the gene EGFR and neoplasm.